Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Sulfated polysaccharides, particularly those derived from seaweeds (such as fucoidan, carrageenan, and ulvan), have been investigated for their therapeutic potential in inflammatory bowel disorders (IBD), including Crohn’s disease and ulcerative colitis. Several preclinical studies in animal models have demonstrated that these compounds can reduce inflammation, decrease oxidative stress, and modulate immune responses in the gut. Mechanistically, sulfated polysaccharides are believed to inhibit pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-1β) and reduce the infiltration of inflammatory cells into intestinal tissues. Some evidence also points to their ability to enhance the intestinal barrier function and promote the growth of beneficial gut microbiota. Limited early-stage clinical trials and pilot studies in humans suggest possible benefits, such as symptom relief and improved markers of inflammation, but the data remain preliminary. Most studies to date are small, lack rigorous controls, or are conducted in animal models, so definitive conclusions about efficacy and safety in humans are not yet possible. Major systematic reviews note the promise of these compounds but emphasize the need for larger, well-designed human clinical trials. In summary, while sulfated polysaccharides have shown anti-inflammatory and gut-protective effects in laboratory and animal studies, human evidence is currently limited. Thus, their use for IBD is supported by moderate scientific evidence, warranting further research before routine clinical application.

More about Sulfated polysaccharide
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Sulfated polysaccharide

Products containing Sulfated polysaccharide